Health & Life Sciences

Across the Middle East, investment in health is expanding far beyond hospitals and traditional healthcare services.

Governments are developing new models of care while also investing in pharmaceutical manufacturing, biotechnology, genomics, medical technology, digital health, diagnostics, research and more resilient healthcare supply chains.

For companies operating in the sector, this creates opportunity across a much wider ecosystem.

But it also makes the market more complex.

A pharmaceutical company, medical-device manufacturer, biotech business, healthcare provider or cosmetics brand may all see potential in the same region, but they will face very different routes to market.

Understanding the opportunity starts with understanding how the health ecosystem works around it.

Healthcare has become closely connected to economic diversification, technology and national resilience across the Middle East.

Saudi Arabia’s health transformation agenda is developing alongside a dedicated National Biotechnology Strategy, with priorities including genomics, vaccines, biomanufacturing and localisation.

The UAE’s National Genome Strategy is designed to accelerate personalised, preventive and precision medicine, while Abu Dhabi is developing a broader life-sciences ecosystem spanning biotechnology, pharmaceuticals, MedTech, genomics and advanced therapies.

Qatar’s National Health Strategy 2024–2030 includes digital health, health intelligence, research and innovation, biotechnology investment, medicine security and greater private-sector participation.

Oman’s long-term Health Vision 2050 addresses healthcare capacity, technology, workforce, chronic disease and the future development of the national health system.

Egypt is placing increasing emphasis on pharmaceutical and medical manufacturing, biopharmaceutical localisation, technology transfer and stronger export capability.

Bahrain is also investing in genomics, preventive care, digital transformation and precision medicine as part of the development of its healthcare system.

The sector is becoming broader.

A healthcare opportunity may now involve:

Care delivery

Hospitals, clinics, specialised care, diagnostics and new models of healthcare delivery.

Medical technology

Devices, equipment, diagnostics, laboratory technologies and connected health solutions.

Pharmaceuticals

Medicines, generics, specialty therapies, APIs and pharmaceutical manufacturing.

Biotechnology

Genomics, vaccines, biomanufacturing, advanced therapies and research platforms.

Digital health

AI, health data, remote care, clinical platforms and technologies that improve how care is delivered.

Preventive & precision medicine

Earlier detection, genomic medicine and treatments increasingly adapted to individual patient profiles.

Consumer health & cosmetics

Products sitting between healthcare, wellness and regulated consumer markets.

Different segments.

Different buyers.

Different regulators.

Different commercial models.

That is why Health & Life Sciences cannot be approached as one single market.

A company can identify strong demand and still be a long way from being able to sell.

Depending on the product and market, the commercial route may involve:

Product classification.

Registration or marketing authorisation.

Technical documentation.

Quality and manufacturing requirements.

Labelling.

Local importer or representative arrangements.

Pricing requirements.

Healthcare-facility approvals.

Tender or procurement processes.

Post-market obligations.

And those requirements differ by country and product category.

A pharmaceutical product will not follow the same route as a medical device.

A diagnostic product can differ again.

Cosmetics, supplements and consumer-health products may fall under completely different frameworks.

Market access is not the same thing as market demand.

Both need to be understood before the company commits.

Healthcare markets contain several different routes to the customer.

Government & public healthcare

Public hospitals, health authorities and centralised procurement systems can play a significant role in purchasing medicines, equipment and healthcare solutions.

Private healthcare groups

Hospital groups, clinics, laboratories and specialist providers create another commercial ecosystem with their own purchasing and decision structures.

Distributors & importers

For many products, the right local distributor remains an important part of registration, market access, logistics and commercial development.

Pharmacies & retail

Consumer health, cosmetics and selected pharmaceutical categories may depend much more heavily on pharmacy networks and retail distribution.

Healthcare professionals

Physicians, pharmacists, laboratory professionals and other practitioners can influence adoption even where they are not the final purchaser.

Patients & consumers

Digital health, wellness and consumer-facing products increasingly create more direct relationships with the end user.

Knowing who uses the product is not enough. You also need to know who influences it, approves it and ultimately pays for it.

Medicine security and local production have become strategic priorities in several Middle Eastern markets.

Saudi Arabia’s biotechnology strategy explicitly includes biomanufacturing and localisation, while Egypt is actively expanding domestic pharmaceutical production and localising biopharmaceutical manufacturing.

Qatar’s National Health Strategy also identifies medicine security and investment in biotechnology among its priorities.

This creates opportunities for companies involved in:

Drug manufacturing.

Contract manufacturing.

Active pharmaceutical ingredients.

Vaccines.

Biologics.

Packaging.

Production technology.

Cold-chain logistics.

Laboratory infrastructure.

Technology transfer.

For some pharmaceutical companies, the regional question is moving from “Where can we sell?” to “Where should we build capability?”

But localisation will not make sense for every business.

Expected volume, product category, procurement opportunities, investment requirements and long-term market potential all need to support the decision.

Biotechnology is becoming more visible in regional healthcare strategies.

Saudi Arabia has identified genomics, vaccines and biomanufacturing among its national biotechnology priorities.

The UAE’s National Genome Strategy is creating a long-term framework around genomic research and precision medicine, while Abu Dhabi is developing infrastructure around genomics, biobanking, clinical research, advanced therapies and drug discovery.

Qatar is similarly investing in biotechnology, research infrastructure and precision-health capabilities.

Bahrain’s National Genome Project is also designed to support earlier detection, prevention, research and increasingly personalised healthcare.

The life sciences opportunity is beginning to extend from importing innovation to participating in it.

For international biotech companies, this can create opportunities around research partnerships, clinical development, technology transfer, manufacturing and commercialisation.

Digital transformation is another common direction across regional health systems.

AI-assisted diagnosis.

Remote care.

Connected medical devices.

Electronic health information.

Clinical decision support.

Population health data.

Automation.

Digital patient journeys.

Precision medicine.

Qatar’s current national strategy includes digitally empowered patients, digitally enabled productivity, health intelligence and integrated health data.

Abu Dhabi is actively developing AI-enabled healthcare and life-sciences infrastructure around genomics, clinical data and real-world evidence.

Bahrain has similarly identified digital health and AI as areas supporting the future development of its health system.

For technology companies, however, healthcare creates another layer of questions around regulation, clinical relevance, data, integration and adoption.

A technically strong solution still needs to fit the healthcare environment in which it will be used.

The Middle East should not be treated as one healthcare market.

Countries differ in:

Regulatory authorities.

Product-registration processes.

Public and private healthcare structures.

Procurement systems.

Insurance and reimbursement.

Domestic manufacturing capability.

Distribution models.

Healthcare infrastructure.

Research ecosystems.

Population-health priorities.

Digital-health maturity.

A company may therefore have a strong opportunity across several Middle Eastern markets while requiring a different entry route in each.

The regulatory route

What needs to be registered, approved or validated before the product can reach the market?

The buyer

Who actually makes the purchasing decision?

The route to market

Does the company need a distributor, importer, local entity, commercial partner or direct presence?

Procurement

Will business primarily come through public tenders, private healthcare groups, distributors, pharmacies or direct commercial relationships?

Market evidence

Is there genuine demand for this product, at this price and within this healthcare environment?

Localisation

Could local manufacturing, packaging, technology transfer or another form of local participation materially strengthen the opportunity?

The ecosystem

Which regulators, healthcare providers, institutions, research organisations and commercial partners matter?

The timeline

Healthcare opportunities can require regulatory preparation and relationship development long before the first sale.

Major regional platforms remain particularly important in healthcare because they bring regulators, healthcare providers, distributors, manufacturers, investors and technology companies into the same environment.

World Health Expo Dubai brings together healthcare manufacturers, distributors, buyers, clinicians, procurement teams and government delegations from across the global healthcare industry.

Global Health Exhibition in Riyadh focuses on healthcare transformation, investment, medical technologies, digital health and new models of care.

CPHI Middle East brings the pharmaceutical value chain together around areas including APIs, finished dosage, manufacturing equipment, packaging and contract services.

Africa Health ExCon in Egypt connects healthcare and life sciences across areas including pharmaceutical localisation, medical industries, digital transformation, AI and healthcare supply chains.

Beautyworld Dubai is one of the Middle East’s major trade platforms for the beauty, cosmetics and wellness industry. It brings together brands, manufacturers, distributors, retailers, importers and industry professionals across cosmetics and skincare, personal care, fragrance, hair, beauty technology, ingredients, packaging and the whole beauty supply chain.

Healthcare products affect people directly.

That changes the commercial environment.

Evidence matters.

Regulatory credibility matters.

Quality matters.

Clinical confidence matters.

Relationships matter.

And the time between identifying an opportunity and generating meaningful business can be longer than in many other sectors.

A distributor may need to be qualified.

A product may need registration.

A hospital may need to evaluate the solution.

Procurement cycles may need to be understood.

A pharmaceutical company may need to assess whether localisation makes economic sense.